Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiao Chai Hu Ke Fang is a Traditional Chinese Medicine (TCM) formulation developed by the Beijing Hospital of Traditional Chinese Medicine (Capital Medical University). It is a modified version of the classic Xiao Chai Hu Tang (Minor Bupleurum Decoction), specifically optimized for the treatment of post-infectious cough and persistent respiratory symptoms following viral infections such as COVID-19 and influenza. The formula is designed to 'harmonize the Shao Yang' and 'ventilate the Lung' according to TCM principles. Its primary botanical components include *Bupleurum chinense*, *Scutellaria baicalensis*, and *Pinellia ternata*, supplemented with antitussive herbs like *Platycodon grandiflorus* and *Prunus armeniaca*. The preparation exhibits anti-inflammatory, antitussive, and immunomodulatory properties by modulating cytokine production and reducing airway inflammation. In China, it is officially recognized as a hospital-made preparation (院内制剂) and has been widely deployed during public health emergencies for respiratory symptom management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xiao chai hu ke fang.